Date: 2014-11-25
Type of
information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in PLOS ONE
Company: Valneva (France)
Product: VLA15 - Lyme borreliosis vaccine
Action
mechanism: vaccine. Valneva’s vaccine candidate is a multivalent OspA based vaccine.
Disease: Lyme borreliosis
Therapeutic
area: Infectious diseases
Country:
Trial
details:
Latest
news:
- • On November 25, 2014, Valneva announced that an article, presenting for the first time the preclinical data of its novel vaccine candidate for prevention of Lyme borreliosis, was published in PLOS ONE. The article entitled: “Design and development of a novel vaccine for protection against Lyme borreliosis” details for the first time Valneva´s Borrelia/Lyme borreliosis vaccine approach, with design, proof-of-concept studies and preclinical data on protection. The publication reveals that Valneva’s vaccine candidate, a multivalent, protein subunit based vaccine, has the potential to provide protection against the majority of Borrelia species pathogenic for humans.
The Borrelia program is part of the strategic alliance agreement signed in 2007 with Novartis. Under this agreement, Novartis gets opt-in rights for the development, manufacturing and commercialization of Valneva Austria GmbH’s non-partnered novel vaccine candidates after the completion of Phase II clinical trials (or earlier at Novartis’s discretion).
Is
general: Yes
